115 related articles for article (PubMed ID: 2374140)
1. Antiandrogenic steroidal sulfonylpyrazoles.
Christiansen RG; Bell MR; D'Ambra TE; Mallamo JP; Herrmann JL; Ackerman JH; Opalka CJ; Kullnig RK; Winneker RC; Snyder BW
J Med Chem; 1990 Aug; 33(8):2094-100. PubMed ID: 2374140
[TBL] [Abstract][Full Text] [Related]
2. The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs.
Juniewicz PE; McCarthy M; Lemp BM; Barbolt TA; Shaw C; Hollenbaugh DM; Winneker RC; Reel JR; Batzold FH
Endocrinology; 1990 May; 126(5):2625-34. PubMed ID: 1691701
[TBL] [Abstract][Full Text] [Related]
3. Endocrine profile of Win 49596 in the rat: a novel androgen receptor antagonist.
Snyder BW; Winneker RC; Batzold FH
J Steroid Biochem; 1989 Dec; 33(6):1127-32. PubMed ID: 2615357
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor binding and antiandrogenic activity of some 4,5-secoandrostanes and ring B cyclopropanoandrostanes.
Stárka L; Hampl R; Kasal A; Kohout L
J Steroid Biochem; 1982 Sep; 17(3):331-4. PubMed ID: 6215537
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of action of Win 49596: a steroidal androgen receptor antagonist.
Winneker RC; Wagner MM; Batzold FH
J Steroid Biochem; 1989 Dec; 33(6):1133-8. PubMed ID: 2615358
[TBL] [Abstract][Full Text] [Related]
6. 5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency.
Lemus AE; Enríquez J; García GA; Grillasca I; Pérez-Palacios G
J Steroid Biochem Mol Biol; 1997 Jan; 60(1-2):121-9. PubMed ID: 9182866
[TBL] [Abstract][Full Text] [Related]
7. The effects of histamine H2 receptor antagonists on androgen action in vivo and dihydrotestosterone binding to the rat prostate androgen receptor in vitro.
Sivelle PC; Underwood AH; Jelly JA
Biochem Pharmacol; 1982 Mar; 31(5):677-84. PubMed ID: 6123322
[TBL] [Abstract][Full Text] [Related]
8. Chiral derivatives of 2-cyclohexylideneperhydro-4,7-methanoindenes, a novel class of nonsteroidal androgen receptor ligand: synthesis, X-ray analysis, and biological activity.
Burden PM; Ai TH; Lin HQ; Akinci M; Costandi M; Hambley TM; Johnston GA
J Med Chem; 2000 Nov; 43(24):4629-35. PubMed ID: 11101354
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogenic properties of nomegestrol acetate.
Duc I; Botella J; Bonnet P; Fraboul F; Delansorne R; Paris J
Arzneimittelforschung; 1995 Jan; 45(1):70-4. PubMed ID: 7893274
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.
Zhang X; Li X; Allan GF; Sbriscia T; Linton O; Lundeen SG; Sui Z
J Med Chem; 2007 Aug; 50(16):3857-69. PubMed ID: 17636947
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor.
Teutsch G; Goubet F; Battmann T; Bonfils A; Bouchoux F; Cerede E; Gofflo D; Gaillard-Kelly M; Philibert D
J Steroid Biochem Mol Biol; 1994 Jan; 48(1):111-9. PubMed ID: 8136296
[TBL] [Abstract][Full Text] [Related]
12. The antiandrogenic effects of delta 1-testolactone (Teslac) in vivo in rats and in vitro in human cultured fibroblasts, rat mammary carcinoma cells, and rat prostate cytosol.
Vigersky RA; Mozingo D; Eil C; Purohit V; Bruton J
Endocrinology; 1982 Jan; 110(1):214-9. PubMed ID: 7053985
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders.
Battmann T; Branche C; Bouchoux F; Cerede E; Philibert D; Goubet F; Teutsch G; Gaillard-Kelly M
J Steroid Biochem Mol Biol; 1998 Jan; 64(1-2):103-11. PubMed ID: 9569015
[TBL] [Abstract][Full Text] [Related]
14. A comparison of in vitro and in vivo EDSTAC test battery results for detecting antiandrogenic activity.
Charles GD; Kan HL; Schisler MR; Bhaskar Gollapudi B; Sue Marty M
Toxicol Appl Pharmacol; 2005 Jan; 202(1):108-20. PubMed ID: 15589981
[TBL] [Abstract][Full Text] [Related]
15. Antiandrogenic activity of a series of des-A-steroid derivatives.
Morales-Alanis H; Brienne MJ; Jacques J; Bouton MM; Nédélec L; Torelli V; Tournemine C
J Med Chem; 1985 Dec; 28(12):1796-803. PubMed ID: 4068004
[TBL] [Abstract][Full Text] [Related]
16. Effect of the steroidal androgen receptor antagonist Win 49,596 on steroid-induced benign prostatic hyperplasia in the castrate beagle dog.
Juniewicz PE; Lemp BM; Barbolt TA; LaBrie TK; McCarthy M; Reel JR; Batzold FH
Prostate; 1990; 16(1):1-14. PubMed ID: 1689481
[TBL] [Abstract][Full Text] [Related]
17. Hershberger assay to investigate the effects of endocrine-disrupting compounds with androgenic or antiandrogenic activity in castrate-immature male rats.
Gray LE; Furr J; Ostby JS
Curr Protoc Toxicol; 2005 Dec; Chapter 16():Unit16.9. PubMed ID: 20963763
[TBL] [Abstract][Full Text] [Related]
18. Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size.
Cabeza M; Zambrano A; Heuze I; Carrizales E; Palacios A; Segura T; Valencia N; Bratoeff E
Steroids; 2009 Oct; 74(10-11):793-802. PubMed ID: 19406144
[TBL] [Abstract][Full Text] [Related]
19. Relative potency of antiandrogens with reference to intracellular testosterone in the rat prostate.
Kondo Y; Homma Y; Aso Y; Kawabe K; Mieda M; Takahashi H
Prostate; 1996 Sep; 29(3):146-52. PubMed ID: 8827082
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor affinity of 5'-acyl furanosteroids.
Kumar V; Ackerman JH; Alexander MD; Bell MR; Christiansen RG; Dung JS; Jaeger EP; Herrmann JL; Krolski ME; McKloskey P
J Med Chem; 1994 Nov; 37(24):4227-36. PubMed ID: 7990121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
